About Dean Hakanson
Dean Hakanson, MD, is chief medical officer of GOA Therapeutics, a West Palm Beach company developing drugs for alcohol intoxication and poisoning. He runs medical affairs and sets medical strategy for the company. He also oversees the Drug Development Board, publication plans and scientific congress plans. He holds a medical degree from the University of Colorado and is board certified in anesthesiology.
Before GOA, Hakanson was a vice president at Gilead Sciences, where he headed U.S. medical affairs. He helped lead U.S. medical affairs work when remdesivir was rolled out in the COVID-19 pandemic. At Novartis he was a vice president and led health economics and outcomes research. The role was for U.S. medical and drug regulatory affairs. At Bristol-Myers Squibb he was a vice president of healthcare access. At Genentech he led the value-based healthcare and payer field team. He also held senior leadership roles at GlaxoSmithKline and was a partner at ZS Associates. He was chief medical officer at Otonomy and at COEUS.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Dean Hakanson in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Dean Hakanson works with at each company, as listed on that company's latest Form D.
